Mirum Pharmaceuticals, Inc. (MIRM) shareholders
Close on Nov 17, 2026Market cap $5.97BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 6,065,308 | 11.80% | 13G (passive) amendment | Dec 31, 2025 |
| JANUS HENDERSON GROUP Ltd. | 5,909,184 | 9.70% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick J. Heron Joint filing with James N. Topper (6.70%), Frazier Life Sciences IX, L.P. (5.90%) and 2 more | 4,108,404 | 6.80% | 13D (active) amendment | Jan 23, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (6.20%) | 3,777,851 | 6.20% | 13G (passive) | Jun 30, 2026 |
| James N. Topper Joint filing with Patrick J. Heron (7.60%), Fhmls Ix, L.P. (7.10%) and 5 more | 3,735,220 | 7.40% | 13D (active) amendment | Nov 1, 2025 |
| BlackRock, Inc. | 3,465,559 | 5.70% | 13G (passive) amendment | Mar 31, 2026 |
| Finny Kuruvilla, M.D., Ph. D. Joint filing with Eventide Asset Management, LLC (5.43%), Robin C. John (5.43%) | 2,606,938 | 5.43% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MIRM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,679,684 | 11.83% | $899.06M | – | 19.58% |
| Jupiter Topco LLC | 5,909,184 | 9.10% | $691.67M | New | 0.28% |
| BlackRock, Inc. | 4,390,063 | 6.76% | $513.94M | +543,533 | 0.01% |
| FMR LLC | 3,670,314 | 5.65% | $429.68M | +1,704,939 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 2,655,607 | 4.09% | $310.89M | +938,186 | 0.03% |
| Vanguard Portfolio Management LLC | 2,377,019 | 3.66% | $278.28M | +944,936 | 0.01% |
| Vanguard Capital Management LLC | 2,254,109 | 3.47% | $263.89M | −160,667 | 0.01% |
| State Street Corp | 2,170,689 | 3.34% | $254.12M | +226,408 | 0.01% |
| William Blair Investment Management, LLC | 1,404,741 | 2.16% | $164.45M | +1,069,072 | 0.49% |
| Geode Capital Management, LLC | 1,393,908 | 2.15% | $163.21M | +133,905 | 0.01% |
| Invesco Ltd. | 1,364,084 | 2.10% | $159.69M | +1,078,848 | 0.01% |
| Wellington Management Group Llp | 1,309,987 | 2.02% | $153.36M | −24,822 | 0.03% |
| Eventide Asset Management, LLC | 1,248,389 | 1.92% | $146.20M | −160,482 | 1.95% |
| Tang Capital Management LLC | 1,236,027 | 1.90% | $144.70M | – | 6.57% |
| Capital World Investors | 1,153,480 | 1.78% | $135.04M | +429,065 | 0.02% |
| Franklin Resources Inc | 1,152,770 | 1.78% | $134.95M | +437,966 | 0.03% |
| Novo Holdings A/S | 1,125,000 | 1.73% | $131.70M | −200,000 | 7.65% |
| TCG Crossover Management, LLC | 1,062,049 | 1.64% | $124.33M | – | 2.99% |
| Bvf Inc/Il | 1,056,027 | 1.63% | $123.63M | −528,700 | 3.16% |
| Polar Capital Holdings Plc | 845,524 | 1.30% | $98.99M | +562,040 | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 327 | 71M | 100.0% | 62 / 127 | 100 / 43 | 17M | 7M |
| Q1 2026 | 311 | 68M | 100.0% | 68 / 115 | 88 / 36 | 16M | 6M |
| Q4 2025 | 283 | 61M | 94.0% | 61 / 104 | 79 / 42 | 8M | 4M |
| Q3 2025 | 272 | 57M | 88.5% | 74 / 91 | 77 / 14 | 7M | 5M |
| Q2 2025 | 214 | 55M | 85.3% | 35 / 77 | 79 / 33 | 4M | 3M |
| Q1 2025 | 214 | 54M | 83.4% | 35 / 86 | 65 / 24 | 6M | 4M |
| Q4 2024 | 205 | 53M | 81.6% | 44 / 73 | 61 / 15 | 4M | 4M |
| Q3 2024 | 178 | 53M | 82.2% | 36 / 75 | 42 / 18 | 9M | 6M |
| Q2 2024 | 161 | 54M | 82.9% | 25 / 66 | 49 / 35 | 7M | 7M |
| Q1 2024 | 172 | 54M | 83.3% | 23 / 69 | 53 / 36 | 8M | 5M |
| Q4 2023 | 187 | 51M | 79.0% | 45 / 70 | 51 / 16 | 10M | 7M |
| Q3 2023 | 159 | 49M | 75.4% | 32 / 68 | 31 / 17 | 17M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
366 funds held MIRM in Q2 2026, 33% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MIRM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,648,210 | 2.54% | $192.96M | 0.01% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,305,682 | 2.01% | $132.53M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,218,782 | 1.88% | $142.68M | 0.17% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,189,194 | 1.83% | $139.22M | 0.07% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,123,070 | 1.73% | $131.48M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,059,206 | 1.63% | $124.00M | 1.16% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 823,454 | 1.27% | $96.40M | 0.66% | Jun 30, 2026 |
| Janus Henderson Triton Fund | 791,874 | 1.22% | $92.70M | 1.56% | Jun 30, 2026 |
| Eventide Gilead Fund | 709,135 | 1.09% | $83.02M | 2.41% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 686,321 | 1.06% | $80.35M | 0.17% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 563,960 | 0.87% | $59.75M | 0.68% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 558,993 | 0.86% | $65.44M | 1.13% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 551,186 | 0.85% | $64.53M | 0.07% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 530,258 | 0.82% | $62.08M | 3.47% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 518,804 | 0.80% | $54.97M | 0.16% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Peetz | CHIEF EXECUTIVE OFFICER, Director | 394,137 | 0.61% | Nov 4, 2026 |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 16,728 | 0.03% | Oct 19, 2026 |
| Robert Paul Myers | Chief Medical Officer | 55 | 0.00% | Oct 14, 2026 |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 44,745 | 0.07% | Sep 15, 2026 |
| Peter Radovich | PRESIDENT AND COO | 57,260 | 0.09% | Jun 8, 2026 |
| Joanne Quan | CHIEF MEDICAL OFFICER | 18,864 | 0.03% | Mar 17, 2026 |
| Saira Ramasastry | Director | 0 | – | Nov 17, 2026 |
| Laura Brege | Director | 15,703 | 0.02% | Nov 13, 2026 |
| Laurent Fischer | Director | 10,727 | 0.02% | Jun 17, 2026 |
| Timothy P. Walbert | Director | 9,680 | 0.01% | Jun 17, 2026 |
| Lon Cardon | Director | 9,680 | 0.01% | Jun 17, 2026 |
| William Fairey | Director | 2,500 | 0.00% | Jun 17, 2026 |
| Michael G. Grey | Director | 330,160 | 0.51% | Jun 17, 2026 |
| Patrick J. Heron | Director | 4,031,625 | 6.21% | Jun 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Saira Ramasastry Director | Nov 16, 2026 | Sale(10b5-1 plan) | −2,000 | $92.28 | $184.56K | 0 |
| Saira Ramasastry Director | Nov 16, 2026 | Option exercise | +2,000 | $28.97 | $57.94K | 2,000 |
| Laura Brege Director | Nov 11, 2026 | Sale | −3,260 | $94.74 | $308.85K | 15,703 |
| Laura Brege Director | Nov 11, 2026 | Sale | −10,907 | $94.05 | $1.03M | 18,963 |
| Laura Brege Director | Nov 11, 2026 | Option exercise | +14,167 | $16.71 | $236.73K | 29,870 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Nov 4, 2026 | Sale(10b5-1 plan) | −20,000 | $90.00 | $1.80M | 206,637 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Nov 4, 2026 | Option exercise | +20,000 | $2.94 | $58.72K | 226,637 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Oct 16, 2026 | Option exercise | +16,112 | $19.24 | $309.99K | 16,728 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Oct 6, 2026 | Option exercise | +6,892 | $15.87 | $109.38K | 206,637 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Oct 6, 2026 | Option exercise | +5,305 | $19.19 | $101.80K | 199,745 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Sep 14, 2026 | Sale | −9,943 | $98.37 | $978.09K | 44,745 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Sep 11, 2026 | Option exercise | +18,333 | – | – | 54,688 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Sep 2, 2026 | Sale(10b5-1 plan) | −658 | $100.00 | $65.80K | 616 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −21,688 | $98.91 | $2.15M | 194,440 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2026 | Option exercise | +30,000 | $2.94 | $88.20K | 224,440 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −8,312 | $98.08 | $815.24K | 216,128 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Aug 18, 2026 | Option exercise | +40,000 | $6.27 | $250.80K | 41,274 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Aug 18, 2026 | Sale | −40,000 | $100.00 | $4.00M | 1,274 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Aug 11, 2026 | Sale(10b5-1 plan) | −6,001 | $99.90 | $599.50K | 36,355 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −2,300 | $100.14 | $230.32K | 194,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −11,683 | $98.51 | $1.15M | 202,626 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Option exercise | +20,000 | $2.94 | $58.80K | 214,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −6,017 | $99.25 | $597.19K | 196,609 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Aug 3, 2026 | Sale(10b5-1 plan) | −1,840 | $105.29 | $193.73K | 1,274 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −3,124 | $121.67 | $380.10K | 44,057 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −1,048 | $122.43 | $128.31K | 43,009 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −528 | $123.84 | $65.39K | 42,481 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −300 | $124.94 | $37.48K | 42,181 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −1,975 | $123.74 | $244.39K | 196,019 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −1,710 | $124.79 | $213.39K | 194,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −4,181 | $122.34 | $511.50K | 197,994 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −12,134 | $121.65 | $1.48M | 202,175 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Option exercise | +20,000 | $2.94 | $58.80K | 214,309 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Jul 1, 2026 | Sale(10b5-1 plan) | −2,721 | $120.00 | $326.52K | 3,114 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Jun 17, 2026 | Sale(10b5-1 plan) | −2,594 | $101.95 | $264.46K | 5,835 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 9, 2026 | Option exercise | +2,393 | $26.49 | $63.39K | 47,181 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale(10b5-1 plan) | −1,567 | $95.12 | $149.05K | 44,788 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale(10b5-1 plan) | −2,258 | $92.84 | $209.63K | 47,530 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale(10b5-1 plan) | −1,175 | $93.95 | $110.39K | 46,355 |
| Peter Radovich PRESIDENT AND COO | Jun 5, 2026 | Option exercise | +16,988 | $19.19 | $326.00K | 57,260 |
| Saira Ramasastry Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,977 | $100.00 | $397.70K | 0 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −2,602 | $94.64 | $246.25K | 221,707 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −16,595 | $95.34 | $1.58M | 205,112 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −6,926 | $96.15 | $665.93K | 198,186 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,973 | $97.56 | $192.49K | 196,213 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,021 | $98.20 | $100.26K | 195,192 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −883 | $99.66 | $88.00K | 194,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Option exercise | +30,000 | $2.94 | $88.20K | 224,309 |
| Saira Ramasastry Director | May 29, 2026 | Option exercise | +3,977 | – | – | 3,977 |
| Timothy P. Walbert Director | May 29, 2026 | Option exercise | +3,977 | – | – | 9,680 |
| Lon Cardon Director | May 29, 2026 | Option exercise | +3,977 | – | – | 9,680 |
| Laurent Fischer Director | May 29, 2026 | Option exercise | +3,977 | – | – | 10,727 |
| Saira Ramasastry Director | May 15, 2026 | Sale(10b5-1 plan) | −2,000 | $109.47 | $218.94K | 0 |
| Saira Ramasastry Director | May 15, 2026 | Option exercise | +2,000 | $23.51 | $47.02K | 2,000 |
| Saira Ramasastry Director | Apr 15, 2026 | Option exercise | +2,000 | $23.51 | $47.02K | 2,000 |
| Saira Ramasastry Director | Apr 15, 2026 | Sale(10b5-1 plan) | −2,000 | $96.90 | $193.80K | 0 |
| Saira Ramasastry Director | Mar 16, 2026 | Sale(10b5-1 plan) | −2,000 | $90.76 | $181.52K | 0 |
| Saira Ramasastry Director | Mar 16, 2026 | Option exercise | +2,000 | $23.51 | $47.02K | 2,000 |
| Peter Radovich PRESIDENT AND COO | Mar 16, 2026 | Sale | −16,515 | $91.98 | $1.52M | 40,272 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Mar 16, 2026 | Sale | −4,732 | $91.98 | $435.25K | 8,429 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Mirum Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 44,759 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher Peetz Officer, Director | Nov 4, 2026 | 20,000 | $1.80M | Nov 4, 2026 | Stock Option Exercise |
| Joanne Quan Former Officer | Nov 4, 2026 | 14,684 | $1.42M | Nov 4, 2026 | Restricted Stock Units vesting under registered plan |
| Eric Bjerkholt Officer | Sep 15, 2026 | 9,943 | $978.09K | Sep 14, 2026 | Restricted Stock Units vesting under registered plan |
| Jolanda Howe Officer | Sep 2, 2026 | 658 | $65.80K | Sep 2, 2026 | Restricted Stock |
| Christopher Peetz Officer, Director | Sep 1, 2026 | 30,000 | $2.96M | Sep 1, 2026 | Stock Option Exercise |
| Jolanda Howe Officer | Aug 18, 2026 | 40,000 | $4.00M | Aug 18, 2026 | Stock Option Exercise |
| Eric Bjerkholt Officer | Aug 11, 2026 | 6,001 | $599.51K | Aug 11, 2026 | Restricted Stock |
| Christopher Peetz Officer, Director | Aug 10, 2026 | 20,000 | $1.98M | Aug 10, 2026 | Stock Option Exercise |
| Jolanda Howe Officer | Aug 3, 2026 | 1,840 | $193.73K | Aug 3, 2026 | Restricted Stock |
| Eric Bjerkholt Officer | Jul 6, 2026 | 5,000 | $611.27K | Jul 6, 2026 | Restricted Stock |
| Christopher Peetz Officer, Director | Jul 6, 2026 | 20,000 | $2.45M | Jul 6, 2026 | Stock Option Exercise |
| Jolanda Howe Officer | Jul 1, 2026 | 2,721 | $326.52K | Jul 1, 2026 | Performance Shares |
| Jolanda Howe Officer | Jun 17, 2026 | 2,594 | $264.46K | Jun 17, 2026 | Performance Shares |
| Eric Bjerkholt Officer | Jun 8, 2026 | 5,000 | $469.07K | Jun 8, 2026 | Restricted Stock |
| Saira Ramasastry Director | Jun 1, 2026 | 3,977 | $397.70K | Jun 1, 2026 | Restricted Stock |
See a number that looks wrong?